licensing

News

GSK grows pipeline with 35Pharma takeover, Frontier deal

GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.

News

Astellas bets on Vir cancer drug, and other licensing deals

Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

News

Madrigal builds in MASH with $4.4bn+ Ribo alliance

Already sitting on a blockbuster therapy for MASH, Madrigal has beefed up its pipeline with six siRNA candidates licensed from China's Ribo.

News

AZ deepens Chinese ties, signs $18.5bn CSPC obesity deal

AstraZeneca deepens ties with China, pledging $15bn in investment and signing a big $18.5bn alliance with CSPC Pharma for obesity and diabetes drugs.

News

Boehringer signs €1bn+ deal for Simcere IBD candidate

Boehringer Ingelheim has sourced an IL-23p19xTL1A bispecific antibody for inflammatory bowel disease, from China's Simcere, for €42m upfront.

News

AstraZeneca pays $630m to get full control of AbelZeta CAR-T

AstraZeneca's push into CAR-T therapies for cancer has continued with an agreement to take full control of C-CAR031 from Chinese partner AbelZeta.

GSK grows pipeline with 35Pharma takeover, Frontier deal

Astellas bets on Vir cancer drug, and other licensing deals

Madrigal builds in MASH with $4.4bn+ Ribo alliance

AZ deepens Chinese ties, signs $18.5bn CSPC obesity deal

Boehringer signs €1bn+ deal for Simcere IBD candidate

AstraZeneca pays $630m to get full control of AbelZeta CAR-T

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

licensing

Editor's Picks